TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback
TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an additional $100 million buyback authorization.Trading volume reached 1.78 million shares, compared with an average of 2.06 million, according to Benzinga Pro.The company said it repurchased roughly 3.5 million shares under the initial program, paying an average price of $28.55 per share.Also Read: Briumvi’s Strong Sales Can’t Stop TG Therapeutics Stock SlideBuilding on that move, the Board of Directors approved a new authorization that will allow the repurchase of another $100 million in common stock.The announcement comes as the company continues to emphasize the commercial opportunity of Briumvi, its multiple sclerosis therapy, which management has positioned as a key growth driver.Michael S. Weiss, Chairman ...Full story available on Benzinga.com
